ONCOS-102 is under clinical development by Targovax and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase II drugs for Epithelial Ovarian Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ONCOS-102’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ONCOS-102 overview

ONCOS-102 is under development for the treatment of solid tumours including malignant pleural mesothelioma, refractory advanced melanoma, peritoneal cancer, epithelial ovarian cancer and metastatic colorectal cancer. It is administered through intratumoral and intraperitoneal injection. ONCOS-102 is an genetically modified oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor and is developed based on virus-based immunotherapy platform. It was also under development for soft tissue sarcoma and metastatic castration-resistant prostate cancer (second and third line therapy).

Targovax overview

Targovax is a developer and commercializer of immunotherapies for the treatment of cancer patients. The company’s lead candidates include TG01, a peptide-based therapeutic anti-cancer vaccine under development for pancreatic cancer; and ONCOS-102 is an adenovirus-based pipeline product for solid tumor indications. It also provides TG02 and ONCOS-200 for other cancer indications. Targovax develops immunotherapies based on treatment approaches harnessing the patient’s immune system to target cancer cells, which include a virus-based immunotherapy platform based on engineered oncolytic viruses for solid tumors; and a peptide-based immunotherapy platform for RAS-mutated cancers. The company has operations in Norway and Finland. Targovax is headquartered in Oslo, Norway.

For a complete picture of ONCOS-102’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.